Epi CanaryEpi Canary
  • Home
  • Feed
  • Synthesis
  • Assessments
  • Scopes
  • Reliability
  • Sources
Epi Canary — Epidemic IntelligenceEvidence-led epidemic intelligence. Source-attributed evidence.
Arcede logoMade by Arcede
← Scopes/
Mpox (Clade I and II)Health
  • Overview
  • Synthesis
  • Assessments
  • Evidence

Public note

For situational awareness and research transparency. Not medical advice.

Synthesis · Mpox (Clade I and II)

Clade Ib European multi-mode transmission ongoing; new research confirms MPXV replication in vaginal/ectocervical cells, strengthening non-sexual mucosal route concern.

Tracking clade Ib geographic expansion, sustained human-to-human transmission chains, and antiviral resistance signals.

Updated Apr 22, 2026

Synthesis

DepthL3
L1

Key findings

Africa CDC Outbreak Brief 26 (Apr 22) confirms continued Clade I/Ib burden across AU member states. PubMed (Apr 17) documents MPXV replication and host response in vaginal and ectocervical epithelial cells — mechanistic support for non-sexual community transmission. Clade Ia genomic diversity study from Central African Republic (2019-2024) reveals multi-lineage longstanding reservoir. No direct data on California cluster size, additional EU Clade Ib countries, or India/Mexico corridor cases this cycle. Africa CDC connector was failing (pending) on this run.

L2

Technical analysis

Mucosal replication study (PubMed, Apr 17): MPXV replicates efficiently in vaginal and ectocervical epithelial cells, providing mechanistic underpinning for non-sexual genital mucosal contact transmission. This is directly relevant to the non-sexual community/healthcare-associated transmission hypothesis in high-income non-African countries (hyp:mpox:120d:63e49b59c5). It does not confirm documented non-sexual cluster transmission but increases the biological plausibility assessment.

Clade Ia genomic diversity CAR (2019-2024) (PubMed, Apr 17): Multiple lineages documented over 5 years in CAR, indicating a deep, diversified animal reservoir. Neutral to Clade Ib-specific hypotheses but provides reservoir context.

Africa CDC Outbreak Brief 26: Coverage of mpox in AU member states confirms ongoing continental burden. Content details unavailable due to Africa CDC connector failure (pending status), but brief number 26 indicates sustained surveillance cycle.

The 15 open hypotheses span a wide geographic and mechanistic space. Connector issues (Africa CDC failing, PubMed stale at 12.7%, PAHO stale) limit this cycle's ability to update Spain Clade Ib, California, or India hypotheses.

L3

Full appendix

California Clade I cluster (hyp:mpox:90d:6a3f80de6a, conf 6): No CDPH announcement of ≥10 confirmed cases visible in evidence stream. CDC MMWR items from today are off-topic (kratom/kava products, childhood vaccination coverage). ProMED Africa CDC connector is the most likely path for a California signal — ProMED healthy with 23 items last run (Apr 22), but none California-specific per scope summary.

Additional EU/G7 Clade Ib country (hyp:mpox:180d:a7cd2cc84d, conf 5): WHO DON healthy but returned no items today (no_items status). ECDC-level reporting would be the source; no signal this cycle.

Tecovirimat resistance in Europe (hyp:mpox:180d:70e3a57a34, conf 5): No treatment failure report. This resolves Oct 17; horizon still long.

Mexico-US border corridor (hyp:mpox:90d:f36a6150c5, conf 4) and India domestic Clade Ib (hyp:mpox:90d:7b29c8d7fc, conf 5): No new signals. CDC MMWR and WHO DON are the relevant channels; both returned irrelevant content today.

Mucosal replication mechanistic uplift: The Apr 17 PubMed study on vaginal/ectocervical MPXV replication is the most hypothesis-relevant item this cycle and provides biological plausibility support (0.15 magnitude) to the non-sexual transmission hypothesis.

02

Scope signals

Confidence updates contributing to this scope, and the coverage health of the sources backing them.

Confidence updates

HypothesisPriorDirectionMagnitudeReasoning
Clade Ib non-sexual community or healthcare-associated transmission documented in at least one high-income non-African country within 120 days, based on CIDRAP/EurekAlert Dec 2025 evidence of shifting transmission pathways in DRC and Ireland, extended incubation periods, and Spain's ongoing surge driven by vaccination gaps.4support0.15MPXV vaginal/ectocervical replication study increases mechanistic plausibility for non-sexual transmission
At least one confirmed Clade Ib case in the United States linked to the Mexico-US border corridor (distinct from the San Francisco Clade I case) within 90 days, based on Mexico's confirmed Clade Ib Jan 2026, high-volume cross-border movement, and CDC diagnostic pause creating federal detection gaps.4neutral0.05No US Clade Ib case linked to Mexico corridor
India will confirm sustained domestic Clade Ib community transmission (≥3 epidemiologically linked locally-acquired cases without direct foreign travel history) within 90 days, based on: Kerala confirmed Clade Ib Jan 2026 with scientists warning of sustained spread; India surveillance gaps noted by Down To Earth; Pakistan Sindh multi-district Clade Ib on India's western border (25 cases, 9 deaths).5neutral0.05No India locally-acquired Clade Ib case reported

Coverage

No coverage table published.